Conferences
Breast Cancers
GI Cancers
Gynecologic Cancer
Immunology News
Multiple Myeloma
Hematology
Lymphoma
Leukemia
Lung Cancers
Melanoma
Prostate Cancer
Urology
CLL
Precision Medicine
Supportive Care
More...
Giants Cancer Care

Dr. Pardee Provides an Update on CPI-613

Timothy S. Pardee, MD
Published Online: Friday, December 20, 2013
Timothy S. Pardee, MD, Assistant Professor, Hematology & Oncology, Wake Forest University Baptist Medical Center, describes a phase I study of the first-in-class pyruvate dehydrogenase complex inhibitor CPI-613 in patients with advanced hematologic malignancies.

CPI-613 attacks cancer cells in a different way, Pardee says, hitting the mitochondria and altering the ability of the cells to make the building blocks of the next cancer cell. In the trial, 40% of the 21 evaluable, heavily-pretreated patients responded. Researchers also observed several outstanding responses.

Researchers saw some evidence of acute renal failure as well as nausea and diarrhea associated with the trial, however, no myelosuppression was observed. There are a number of ongoing trials using this drug.

Online CME Activities
Free CME from PER
Advances in Multiple Myeloma
Cancer Summaries and Commentaries™: Update from Chicago: Castrate Resistant Prostate Cancer and Advanced Melanoma
Community Practice Connections™: Novel Perspectives in Personalizing EGFR-Targeted Therapy in NSCLC: Frontline and Overcoming Resistance
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Gynecologic Cancers
More Reading
 
$auto_registration$